|| Checking for direct PDF access through Ovid
Migraine headache represents a significant economic burden to patients, healthcare payers and employers. Several pharmacological agents have shown at least some efficacy as prophylactic therapy in patients with frequent, severely disabling migraines. Prophylactic migraine therapies appear to effectively decrease resource use and improve productivity. In particular, the antiepileptic topiramate appears to be a cost-effective intervention for the prevention of migraine.